Burzynski Research Institute Reports $665,318 Net Loss for Six Months Ending August 31, 2025

Burzynski Research Institute, Inc. reported its financial results for the six months ending August 31, 2025, revealing a net loss of approximately $665,318, a decrease from a loss of $741,170 during the same period in 2024. The company's total operating expenses for the first half of 2025 were $665,318, down from $741,170 in the previous year, primarily due to a significant reduction in general and administrative expenses, which fell by 41% to $139,929. Research and development costs increased slightly by 4% to $525,389, attributed to higher personnel costs. The basic and diluted loss per share remained at $(0.01) for both periods.

In terms of financial position, Burzynski Research Institute reported total current assets of $1,331,000 as of August 31, 2025, an increase from $847,000 at the end of February 2025. However, current liabilities also rose significantly to $70,902,000 from $42,484,000, resulting in a working capital deficit of $69,571,000, compared to a deficit of $41,637,000 in the previous period. The accumulated deficit increased to $130,141,731, reflecting the ongoing financial challenges faced by the company.

Strategically, the company continues to rely heavily on funding from its majority shareholder, Dr. S.R. Burzynski, who has financed operations through his medical practice. The Research Funding Agreement with Dr. Burzynski was amended in May 2023 to limit its scope to the United States and Canada, ensuring continued financial support for the development of Antineoplaston drugs. The company has not generated significant revenue since its inception and remains economically dependent on Dr. Burzynski's contributions, which are critical for ongoing clinical trials and operational expenses.

Operationally, the company has faced challenges with its investigational new drug application (IND 43742), which is currently under full clinical hold by the FDA, preventing the enrollment of new patients in clinical trials. The company has not reported any significant customer counts or user statistics, as its operations are primarily focused on research and development rather than commercial sales. The company’s administrative and research facilities are located in Texas, and it has maintained a consistent employee headcount of 131,448,444 shares outstanding.

Looking ahead, Burzynski Research Institute anticipates continued net losses and negative operating cash flows for the foreseeable future. The company estimates it will require approximately $600,000 for the remaining two quarters of the fiscal year ending February 28, 2026. While management expresses hope for ongoing support from Dr. Burzynski, there is no assurance that additional funding will be available, which raises concerns about the company's ability to sustain operations without securing alternative financing.